{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "IQV",
  "name": "IQVIA Holdings Inc.",
  "url": "https://frontierpicks.com/dossiers/IQV/",
  "json_url": "https://frontierpicks.com/dossiers/IQV.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance raised. The 1 December 2026 investor day decides whether that becomes faster 2027 revenue growth.",
  "invalidation_trigger": "A daily close below $240, under the $241.52 close on 2026-08-13, which would erase the three-month gain; or a 2027 framework at the 2026-12-01 investor day pointing to revenue growth below the 6.4%–7.3% guided for 2026.",
  "catalyst_date": "2026-12-01",
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "SEC EDGAR",
      "url": "https://www.sec.gov/Archives/edgar/data/0001478242/000162828026067406/iqv-q3x2026earningspressre.htm",
      "date": null
    },
    {
      "title": "Earnings call transcript: IQVIA tops Q3 2026 estimates and raises outlook",
      "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-iqvia-tops-q3-2026-estimates-and-raises-outlook-93CH-4976019",
      "date": null
    },
    {
      "title": "Finimize",
      "url": "https://finimize.com/content/iqvias-next-big-moment-could-come-at-investor-day",
      "date": null
    },
    {
      "title": "MarketBeat",
      "url": "https://www.marketbeat.com/instant-alerts/analyst-iqvia-nyse-iqv-price-target-raised-to-32500-2026-10-28/",
      "date": "2026-10-28"
    },
    {
      "title": "SEC EDGAR",
      "url": "https://www.sec.gov/Archives/edgar/data/0001668397/000166839726000034/medp-20261021exx991.htm",
      "date": "2026-10-21"
    },
    {
      "title": "Finviz",
      "url": "https://finviz.com/news/411176/fortrea-reports-third-quarter-2026-results",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Q3 2026 net new bookings $3.2B, up 15% year on year; book-to-bill 1.2x; trailing twelve-month bookings $11.7B, up 14%",
      "source": "IQVIA Q3 2026 earnings release, 8-K",
      "as_of": "2026-10-27"
    },
    {
      "claim": "Q3 2026 revenue $4,428M, up 8.0% reported and 8.6% at constant currency, beating the $4,366M estimate; adjusted diluted EPS $3.34 beat the $3.27 estimate; GAAP diluted EPS $2.10",
      "source": "IQVIA Q3 2026 earnings release, 8-K; Benzinga 2026-10-27",
      "as_of": "2026-10-27"
    },
    {
      "claim": "FY2026 guidance raised to revenue $17,350–$17,500M (from $17,275–$17,475M), adjusted EBITDA $4,025–$4,055M, adjusted EPS $12.90–$13.00 (from $12.80–$13.00)",
      "source": "IQVIA Q3 2026 earnings release, 8-K",
      "as_of": "2026-10-27"
    },
    {
      "claim": "R&D Solutions contracted backlog $32.6B after a ~$2.1B removal of long-inactive trials; about $9.4B expected to convert to revenue in the next 12 months, up 10%",
      "source": "IQVIA Q3 2026 earnings release, 8-K",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Q3 2026 R&D Solutions revenue $2,639M, up 8.7% (6.8% excluding pass-throughs); Commercial Solutions $1,789M, up 6.9%",
      "source": "IQVIA Q3 2026 earnings release, 8-K",
      "as_of": "2026-10-27"
    },
    {
      "claim": "Q3 2026 peers: ICON net book-to-bill 1.56x with revenue down 2.9%; Medpace net new awards $873.4M, revenue up 8.5%, backlog up 5.6%; Fortrea book-to-bill 1.12x",
      "source": "ICON, Medpace and Fortrea Q3 2026 results releases",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Price targets after the report: Truist $346, Baird $328, JPMorgan $325, Evercore ISI $310, Deutsche Bank $310, TD Cowen $307, Rothschild & Co Redburn $299",
      "source": "Benzinga, fiscal.ai and MarketBeat 2026-10-28 to 2026-10-29",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Executive James G. Berkshire exercised options on 5,381 shares at $131.82 and sold 2,668 shares in the open market at $261.33 on 2026-09-02",
      "source": "SEC Form 4 filed 2026-09-04",
      "as_of": "2026-09-02"
    }
  ],
  "view_changes": [],
  "frame": null,
  "filed_numbers": {
    "as_of": "2026-11-13",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-13",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-27",
              "restated": null,
              "value_musd": 4428,
              "yoy_pct": 8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-28",
              "restated": null,
              "value_musd": 4368,
              "yoy_pct": 8.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "value_musd": 4151,
              "yoy_pct": 8.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-17",
              "restated": null,
              "value_musd": 4364,
              "yoy_pct": 10.3
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-28",
              "restated": null,
              "value_musd": 4100,
              "yoy_pct": 5.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-22",
              "restated": null,
              "value_musd": 4017,
              "yoy_pct": 5.3
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-27",
              "restated": null,
              "pct": 33.8
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-28",
              "restated": null,
              "pct": 32.9
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 32.6
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-17",
              "restated": null,
              "pct": 32.9
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-28",
              "restated": null,
              "pct": 33.5
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-22",
              "restated": null,
              "pct": 32.9
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-27",
              "restated": null,
              "pct": 12.9
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-28",
              "restated": null,
              "pct": 11.6
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 12.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-17",
              "restated": null,
              "pct": 14.4
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-28",
              "restated": null,
              "pct": 13.5
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-22",
              "restated": null,
              "pct": 12.6
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 386
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "four_quarters_end": "2026-09-30",
          "value_musd": 350,
          "four_quarters_musd": 1394
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "first_end": "2025-12-31",
          "value_musd": 2736
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "first_end": "2025-12-31",
          "value_musd": 657
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "first_end": "2025-12-31",
          "value_musd": 2079
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "base_end": "2025-09-30",
          "pct": -2.7
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 2422
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 16067,
          "composition": "non-current long-term debt plus current maturities"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": -13645
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 2313,
          "yoy_pct": 7.1
        },
        "backlog": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 34200,
          "yoy_pct": -0.6
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 3293
        },
        "inventory": {
          "status": "not reported"
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-27",
          "value_musd": 6660
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "value_musd": 43691.8
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "value_musd": 57336.8
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "multiple": 3.3
        },
        "ev_ebit": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "multiple": 25.8
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "multiple": 31.3
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "multiple": 6.6
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-13",
          "basis_end": "2026-10-20",
          "basis_filed": "2026-10-27",
          "pct": 4.8
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-15",
      "published": "2026-10-26",
      "short_pct_of_outstanding": 1.82,
      "days_to_cover": 2.4,
      "change_pct": -7
    },
    "insiders": {
      "status": "ok",
      "as_of": "2026-11-15",
      "windows": [
        {
          "days": 90,
          "status": "ok",
          "from": "2026-08-18",
          "bought_usd": 0,
          "sold_usd": 1936906.62,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        },
        {
          "days": 365,
          "status": "ok",
          "from": "2025-11-16",
          "bought_usd": 0,
          "sold_usd": 39260702.17,
          "bought_unpriced": 0,
          "sold_unpriced": 0
        }
      ]
    }
  },
  "body_markdown": "## Current Thesis\n\nIQVIA's clinical-research bookings are growing faster than its revenue, which gives the shares modestly better-than-even odds of beating the S&P 500 over the next three months. The 2026-12-01 investor day settles the case. Management will give a broad framework for 2027 there, ahead of detailed guidance with fourth-quarter results.\n\nThird-quarter 2026 bookings rose 15% at a 1.2x book-to-bill ratio, and IQVIA raised its 2026 guidance on 2026-10-27. No results, guidance change or broker target change has been reported since 2026-10-29, per Benzinga and fiscal.ai. The shares closed at $274.53 on 2026-11-11, above the $263.79 close on 2026-11-04.\n\nThe price already reflects a recovery. The shares closed at $274.53 on 2026-11-11, 3.5% below the intraday 52-week high of $284.50 set on 2026-10-27 and well above the 52-week closing low of $156.66 on 2026-04-29. For the shares to lead from here, the 2027 framework has to show faster growth than the 2026 guidance already implies.\n\n## Bull Case\n\n- **Bookings outran revenue again.** Third-quarter net new bookings were $3.2 billion, up 15%, for a 1.2x book-to-bill, per the company's 2026-10-27 8-K. Trailing twelve-month bookings reached $11.7 billion, up 14%.\n- **Guidance went up on 2026-10-27.** IQVIA raised 2026 revenue guidance to $17,350–$17,500 million from $17,275–$17,475 million. It set adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) at $4,025–$4,055 million and adjusted earnings per share (EPS) at $12.90–$13.00, from $12.80–$13.00.\n- **The quarter beat estimates.** Adjusted EPS of $3.34 beat the $3.27 consensus and revenue of $4,428 million beat the $4,366 million consensus, per Benzinga on 2026-10-27. Revenue rose 8.0% as reported and 8.6% at constant currency.\n- **More backlog converts next year.** IQVIA expects about $9.4 billion of R&D Solutions backlog to become revenue over the next twelve months, up 10%, per the 2026-10-27 release.\n- **Demand indicators are rising.** On the 2026-10-27 call, management said request-for-proposal flow rose by a high-single-digit percentage and clinical win rates rose 2 to 3 points. It put emerging biopharma funding at $90 billion so far in 2026, up more than 85%.\n- **Peers report rising awards.** ICON reported a 1.56x net book-to-bill on 2026-10-27, Medpace record net new awards of $873.4 million on 2026-10-21, and Fortrea a 1.12x book-to-bill on 2026-10-29, per their releases.\n- **Broker targets sit above the shares.** Truist moved to $346, Baird to $328, JPMorgan to $325, Evercore ISI to $310 and TD Cowen to $307, per Benzinga on 2026-10-28 and 2026-10-29. Deutsche Bank's target is $310, per MarketBeat on 2026-10-28, and Rothschild & Co Redburn's is $299, per fiscal.ai on 2026-10-28.\n\n## Bear Case\n\n- **Backlog was cut by $2.1 billion.** Contracted R&D Solutions backlog was $32.6 billion at 2026-09-30, after IQVIA removed about $2.1 billion of trials inactive for 18 months or more. The company says the cut does not affect guidance, bookings or next-twelve-month revenue from backlog.\n- **Acquisitions lift the guided growth.** Updated 2026 guidance assumes acquisitions add 2 to 2.5 percentage points of growth, per the 2026-10-27 call. The 2027 framework has to show demand-driven growth on top of that.\n- **Peer conversion is uneven.** ICON's third-quarter revenue fell 2.9% despite its 1.56x book-to-bill, per its 2026-10-27 release. Medpace's backlog grew 5.6%, slower than its 8.5% revenue growth, per its 2026-10-21 8-K.\n- **Commercial Solutions grows more slowly.** The segment's third-quarter revenue was $1,789 million, up 6.9%, against 8.7% for R&D Solutions, per the 2026-10-27 release. R&D Solutions growth was 6.8% excluding reimbursed pass-through costs.\n- **Debt is high.** Net leverage was 3.45x net debt to trailing adjusted EBITDA at 2026-09-30, per the company's 8-K.\n- **Expectations are set high.** RBC Capital Markets, per Finimize, says the direction of the 2027 framework matters more than another beat-and-raise, and that lower growth or margins than bullish forecasts could pressure the shares.\n\n## Setup & Price Structure\n\nThe shares closed at $274.53 on 2026-11-11, 3.5% below the intraday 52-week high of $284.50 reached on 2026-10-27. They are up 13.7% over three months, from a $241.52 close on 2026-08-13. In adjusted daily closes, the 50-day moving average stands at $267.40 and the 200-day at $210.72 as of 2026-11-11, so the shares trade above both.\n\nAfter the report, the shares fell to $263.79 on 2026-11-04 and $264.88 on 2026-11-05. They then rose to $271.83 on 2026-11-06 and $278.84 on 2026-11-09, before easing to $275.15 on 2026-11-10 and $274.53 on 2026-11-11. The $284.50 high is the nearest level overhead; the 50-day average is the nearest level below.\n\nInsider selling is limited. Executive James G. Berkshire exercised options on 5,381 shares at $131.82 on 2026-09-02, sold 2,668 shares in the open market at $261.33 and handed 2,713 shares to the company at $261.54, per his Form 4 filed 2026-09-04. IQVIA bought back $950 million of stock in the first nine months of 2026 and has reported no share issuance.\n\n## Catalyst Calendar\n\n- **2026-12-01:** IQVIA investor day; senior management presentations from 9:00 a.m. to about 12:30 p.m. ET, with a broad framework for 2027. Shows whether two quarters of 1.2x book-to-bill and a rising next-twelve-month backlog become 2027 revenue growth above the 6.4%–7.3% guided for 2026.\n- **~2027-02 (est.):** Fourth-quarter 2026 results and detailed 2027 guidance. Tests whether bookings hold against what management called very difficult fourth-quarter comparisons, and sets the 2027 revenue and EPS targets.\n\n## What Would Change Our Mind\n\nA daily close below $240, under the $241.52 close on 2026-08-13, which would erase the three-month gain; or a 2027 framework at the 2026-12-01 investor day pointing to revenue growth below the 6.4%–7.3% guided for 2026.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Backlog quality: the ~$2.1B inactive-trial removal is followed by further write-downs or rising cancellations. Confirmed by: A second backlog adjustment, or management citing cancellations above the historical range at the 2026-12-01 investor day or the fourth-quarter report.\n- Bookings gains fail to lift revenue growth in 2027. Confirmed by: A 2027 framework at the 2026-12-01 investor day pointing to revenue growth below the 6.4%–7.3% guided for 2026, or growth that leans mainly on acquisitions.\n- The shares already reflect the recovery after a cluster of broker target raises in late October 2026. Confirmed by: No new target raises after the 2026-12-01 investor day, or brokers cutting 2027 estimates after the framework.\n- Industry-wide bookings do not convert to revenue on schedule. Confirmed by: ICON or IQVIA reporting flat or falling revenue again in the fourth quarter despite book-to-bill above 1.0x, or Medpace citing further slowing in backlog conversion.\n- Commercial Solutions slowdown persists. Confirmed by: Segment growth staying below the 6.9% reported in Q3 2026 in the fourth-quarter report.\n- High debt limits flexibility if demand softens. Confirmed by: Net leverage rising back above the 3.45x reported at 2026-09-30.\n\n## Correlation Notes\n\nIQVIA trades with the contract research group: ICON, Medpace, Fortrea and Charles River. Their shared driver is biopharma research spending, which follows emerging biotech funding; IQVIA cited $90 billion raised so far in 2026, up more than 85%. The Commercial Solutions data business ties part of IQVIA to large-pharma budgets. With net leverage at 3.45x, the shares carry more interest-rate sensitivity than less-indebted peers such as Medpace.",
  "first_seen": "2026-11-10",
  "last_analyzed": "2026-11-12T16:50:29+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}